As previously reported, Barclays downgraded Hikma Pharmaceuticals (HKMPF) to Underweight from Equal Weight with a 1,600 GBp price target as the firm transferred coverage of European mid-cap pharma to a new analyst. The firm cites uncertainty around management, strategy and the outlook as well as limited catalysts for its downgrade.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HKMPF:
- Hikma Pharmaceuticals downgraded to Underweight from Equal Weight at Barclays
- Hikma Executive Vice Chairman Buys £1.5m of Company Shares
- Hikma directors restructure pledges over 2.5 million shares via Darhold Limited
- Hikma Pharmaceuticals Announces Share Pledge Transactions by Key Executives
- Hikma Pharmaceuticals Announces Leadership Changes and Board Appointment